0001213900-22-029923.txt : 20220527 0001213900-22-029923.hdr.sgml : 20220527 20220527092210 ACCESSION NUMBER: 0001213900-22-029923 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220527 DATE AS OF CHANGE: 20220527 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Qualigen Therapeutics, Inc. CENTRAL INDEX KEY: 0001460702 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263474527 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88903 FILM NUMBER: 22972918 BUSINESS ADDRESS: STREET 1: 2042 CORTE DEL NOGAL STREET 2: CARLSBAD CITY: CALIFORNIA STATE: CA ZIP: 92011 BUSINESS PHONE: (760) 918-9165 MAIL ADDRESS: STREET 1: 2042 CORTE DEL NOGAL STREET 2: CARLSBAD CITY: CALIFORNIA STATE: CA ZIP: 92011 FORMER COMPANY: FORMER CONFORMED NAME: RITTER PHARMACEUTICALS INC DATE OF NAME CHANGE: 20090402 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALPHA CAPITAL ANSTALT CENTRAL INDEX KEY: 0001140358 IRS NUMBER: 000000000 STATE OF INCORPORATION: N2 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: LETTSTRASSE 32 STREET 2: FL-9490 CITY: VADUZ STATE: N2 ZIP: 00000 BUSINESS PHONE: 011-423-2323195 MAIL ADDRESS: STREET 1: LETTSTRASSE 32 STREET 2: FL-9490 CITY: VADUZ STATE: N2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ALPHA CAPITAL AKTIENGESELLSCHAFT DATE OF NAME CHANGE: 20010510 SC 13G/A 1 ea160727-13ga1alpha_qualigen.htm AMENDMENT NO. 1 TO SCHEDULE 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G/A

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO. 1)

 

QUALIGEN THERAPEUTICS, INC.

 

(Name of Issuer)

  

COMMON STOCK, PAR VALUE $0.001

 

(Title of Class of Securities)

  

74754R103

 

(CUSIP Number)

  

May 26, 2022

 

(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

  

Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

  

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

(Continued on following page(s)

 

Page 1 of 5 Pages

 

 

 

 

 

CUSIP No. 74754R103 13G/A Page 2 of 5 Pages

 

1.NAMES OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

 

Alpha Capital Anstalt

 

2.CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a) ☐

(b) ☐

 

3.SEC USE ONLY

 

 

4.CITIZENSHIP OR PLACE OF ORGANIZATION

 

Liechtenstein

 

5.

SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON – 3,525,042 Shares of Common Stock (1)

 

 

6.SHARED VOTING POWER - None

 

 

7.

SOLE DISPOSITIVE POWER – 3,525,042 Shares of Common Stock (1)

 

 

8.SHARED DISPOSITIVE POWER – None

 

 

9.AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -

 

3,525,042 Shares of Common Stock (1)

 

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☒

 

The aggregate amount in Row 9 represents the maximum amount that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.9% ownership restriction. The full conversion and/or exercise of Alpha Capital Anstalt’s securities would exceed this restriction.

 

11.PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

9.99%

 

12.TYPE OF REPORTING PERSON

 

CO

 

 

(1)Based on 35,295,541 shares outstanding as of May 13, 2022 as disclosed in Form 10-Q filed on May 13, 2022 for the quarter ended March 31, 2022.

 

 

 

 

CUSIP No. 74754R103 13G/A Page 3 of 5 Pages

  

ITEM 1 (a) NAME OF ISSUER: Qualigen Therapeutics, Inc.

 

ITEM 1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

 

2042 Corte Del Nogal, Carlsbad, California CA 92011

 

ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt

 

ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

 

Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein

 

ITEM 2 (c) CITIZENSHIP: Liechtenstein

 

ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, par value $0.001

 

ITEM 2 (e) CUSIP NUMBER: 74754R103

 

ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

 

ITEM 4 OWNERSHIP

 

(a) AMOUNT BENEFICIALLY OWNED: 3,525,042 Shares of Common Stock (1)

 

(b) PERCENT OF CLASS: 9.99% (1)

 

(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

 

(i)SOLE POWER TO VOTE OR DIRECT THE VOTE

 

3,525,042 Shares of Common Stock (1)

 

(ii)SHARED POWER TO VOTE OR DIRECT THE VOTE

 

0 Shares

 

(iii)SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

3,525,042 Shares of Common Stock (1)

 

(iv)SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

 

0 Shares

 

 

 

 

CUSIP No. 74754R103 13G/A Page 4 of 5 Pages

  

ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

 

Not applicable

  

ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

 

Not applicable

  

ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

 

Not applicable

  

ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

 

Not applicable

  

ITEM 9 NOTICE OF DISSOLUTION OF GROUP

 

Not applicable

 

 

 

 

CUSIP No. 74754R103 13G/A Page 5 of 5 Pages

  

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  May 27, 2022
  (Date)
   
  /s/ Konrad Ackermann
  (Signature)
   
  Konrad Ackermann, Director
  (Name/Title)